New Redx director brings scientific, commercial expertise

Redx announced the appointment of a non-executive director on Monday, with Dr Bernhard Kirschbaum joining the firm's board immediately.

The AIM-listed self-described drug discovery and development company said Dr Kirschbaum was bringing with him more than 25 years experience in pharmaceutical research and drug development, primarily at global pharmaceutical companies.

"During his career, he held leadership roles at Merck/Merck Serono, Sanofi-Aventis, Aventis and Hoechst Marion Roussel, and has expertise in a broad range of disease areas including oncology, immuno-oncology, immunology, neurological disorders and cardiometabolic diseases," the company said in a statement.

Redx chief executive Neil Murray said the firm would benefit from his combined scientific and commercial expertise.

"Redx has ambitious plans for growth and I look forward to contributing fully towards the ongoing development of the business," said Dr Kirschbaum.

The appointment came ahead of the anticipated full-year results for Redx, due in the middle of January.